Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

Stopped early · Not applicable · Has a placebo group

Conditions studied: Schizophrenia, Impulsive Behavior

In brief

The purpose of this study is to test whether nicotine, a drug that activates receptors called nicotinic acetylcholine receptors in the brain, improves the ability to make or withhold responses to faces that are either emotionally neutral or emotionally negative. This study will also test whether the drug affects brain activity while making or withholding responses using electroencephalography. Previous studies in people with schizophrenia have shown that more errors in response to negative emotional cues are related to greater likelihood of impulsive aggressive behavior. Therefore, the aim of this study is to determine whether nicotine might be a new strategy to reduce aggressive behavior. The investigators' goal is 25 individuals with schizophrenia and 25 healthy controls to complete the study at Vanderbilt.

Key facts

Study ID
NCT03838484
Run by
Vanderbilt University Medical Center
People needed
18
Starts
2019-05-10
Expected to finish
2020-02-24
Last updated by the study team
2022-04-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.